RTP Biotech Boom: 1,000+ Jobs, Billions Pour into NC Triangle

Genentech, a Roche subsidiary, plans to invest up to $700 million in a new 700,000-square-foot manufacturing facility in Holly Springs, creating 420 high-paying jobs by 2030. The East Coast plant, the company's first in two decades, will produce obesity medicines and could expand based on U.S. policy. State Commerce Department officials approved the project during a Monday Economic Investment Committee meeting, projecting 4,578 direct and indirect jobs for southern Wake County.[1] Novartis Gene Therapies is committing $771 million across Research Triangle Park sites in Durham and Morrisville, targeting up to 700 new jobs in biologics and small-molecule manufacturing, including the spinal muscular atrophy treatment Zolgensma. The state approved a $7.5 million Job Development Investment Grant, with Durham and Wake counties adding $12.6 million in incentives if hiring and investment goals are met by 2030. Average salaries will exceed $111,000, building on Novartis' existing 331 Durham employees and prior incentives from its 2018 AveXis acquisition.[2][3] AbbVie is investing $1.4 billion in a 185-acre pharmaceutical manufacturing campus in Durham, generating 734 jobs over four years. The project expands from the company's North Chicago headquarters, focusing on state-of-the-art production amid fierce competition for Triangle talent.[4][5] Holly Springs is at the epicenter of the frenzy: Amgen's $1.57 billion expansions will add 725 jobs for cancer and heart disease drugs, while Fujifilm Diosynth's $3.2 billion biomanufacturing campus targets 1,400 roles by 2031. These announcements follow News & Observer reports on RTP gene therapy pushes, transforming quiet towns into biotech hubs with lucrative opportunities for North Carolinians.[1][7]